In compliance with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations), we wish to inform you that the Board of Directors in their meeting held today, i.e. February 3, 2020, approved the Scheme of Amalgamation between APL Institute of Clinical Laboratory & Research Private Limited ('the Transferor Company'), a wholly owned subsidiary of the Company and Dr. Lal PathLabs Limited ('the Company/the Transferee Company') with effect from April 1, 2020 ('Appointed Date'), pursuant to Sections 230-232 of the Companies Act, 2013. Dear Sir Please find enclosed herewith Scheme of Amalgamation between Dr. Lal PathLabs Limited ('the Transferee Company') and APL Institute of Clinical Laboratory & Research Private Limited ('the Transferor Company'), a Wholly Owned Subsidiary of the transferee Company with effect from April 1,2020 ('Appointed Date'). The Scheme of Amalgamation is conditional upon and subject to sanction by the Hon''ble National Company Law Tribunal ('NCLT) Delhi & Ahmedabad. (As Per BSE Announcement Dated 11.02.2020) In furtherance to Company''s letters dated February 3, 2020 and February 11, 2020 and in terms of Regulation 30 read with Regulation 37 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that Hon''ble National Company Law Tribunal ('NCLT'), New Delhi Bench-Ill has, vide its order dated May 13, 2022, sanctioned the Scheme of Amalgamation between Dr. Lal PathLabs Limited ('The transferee Company') and APL Institute of Clinical Laboratory & Research Private Limited ('The transferor Company'), a wholly owned subsidiary of the transferee Company. The said sanction, however, is subject to the approval of scheme by NCLT, Ahmedabad also. (As Per BSE Announcement Dated on 13/05/2022) In furtherance to Company''s letters dated February 03, 2020, February 11, 2020 and May 13, 2022 and in terms of Regulation 30 read with Regulation 37 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that Hon''ble National Company Law Tribunal ('NCLT'), Ahmedabad Bench-Il has, vide its order dated March 17, 2023, sanctioned the Scheme of Amalgamation between Dr. Lal PathLabs Limited ('Transferee Company') and APL Institute of Clinical Laboratory & Research Private Limited ('Transferor Company'), a wholly owned subsidiary of Transferee Company. (As Per BSE Announcement Dated on 17.03.2023)